Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE

João Pedro Ferreira*, Jonathan P. Blatchford, John R. Teerlink, Mikhail N. Kosiborod, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Jasper Tromp, Michael E. Nassif, Mitchell A. Psotka, Josep Comin-Colet, Robert J. Mentz, Martina Brueckmann, Matias Nordaby, Piotr Ponikowski, Adriaan A. Voors

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

4 Citaten (Scopus)
28 Downloads (Pure)

Samenvatting

Aims: In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with mineralocorticoid receptor antagonists (MRAs). The interplay between empagliflozin and MRAs in AHF is yet to be explored. This study aimed to evaluate the efficacy and safety of empagliflozin versus placebo according to MRA use at baseline in the EMPULSE trial (NCT04157751).

Methods and results: In this analysis all comparisons were performed between empagliflozin and placebo, stratified by baseline MRA use. The primary outcome included all-cause death, heart failure events, and a ≥5 point difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score at 90 days, assessed using the win ratio (WR). First heart failure hospitalization or cardiovascular death was a secondary outcome. From the 530 patients randomized, 276 (52%) were receiving MRAs at baseline. MRA users were younger, had lower ejection fraction, better renal function, and higher KCCQ scores. The primary outcome showed benefit of empagliflozin irrespective of baseline MRA use (WR 1.46, 95% confidence interval [CI] 1.08–1.97 and WR 1.27, 95% CI 0.93–1.73 in MRA users and non-users, respectively; interaction p = 0.52). The effect of empagliflozin on first heart failure hospitalization or cardiovascular death was not modified by MRA use (hazard ratio [HR] 0.58, 95% CI 0.30–1.11 and HR 0.85, 95% CI 0.47–1.52 in MRA users and non-users, respectively; interaction p = 0.39). Investigator-reported and severe hyperkalaemia events were infrequent (<6%) irrespective of MRA use.

Conclusions: In patients admitted for AHF, initiation of empagliflozin produced clinical benefit and was well tolerated irrespective of background MRA use. These findings support the early use of empagliflozin on top of MRA therapy in patients admitted for AHF.

Originele taal-2English
Pagina's (van-tot)1797-1805
Aantal pagina's9
TijdschriftEuropean Journal of Heart Failure
Volume25
Nummer van het tijdschrift10
DOI's
StatusPublished - okt.-2023

Vingerafdruk

Duik in de onderzoeksthema's van 'Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE'. Samen vormen ze een unieke vingerafdruk.

Citeer dit